Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Sponsor: Bristol-Myers Squibb
Study ID: NCT06361563
Status: Completed

Conditions

Upper Gastrointestinal Cancer

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Nivolumab — DRUG
As per product label

Study Details

The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.

Key Dates

Start date: Sep 5, 2023
Status verified: Apr 2024
Primary completion: Jan 25, 2024
Completion: Jan 25, 2024

Study Design

Enrollment: 250 participants (actual)

Arms

Arm: Participants treated with adjuvant nivolumab

Primary Outcome Measure

Participant sociodemographics [ Time Frame: Baseline ]